Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.

Johnson & Johnson acquired Firefly Bio for $1 billion to gain access to its Firelink degrader antibody conjugate (DAC) platform, which targets KRAS-driven tumors previously considered 'undruggable.' This acquisition supports J&J's goal of generating $50 billion in annual oncology revenue by 2030, as the antibody drug conjugate market is projected to reach $21-35 billion by 2030-2035.